{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.0","upperLimit":"-2.5","value":"-5.8"},{"groupId":"OG001","lowerLimit":"-0.4","upperLimit":"6.7","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average symptom burden index score assesses the following six items (Appetite loss, fatigue, cough, shortness of breath, blood in sputum, pain) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The average symptom burden score is average of all the 6 items ranging from 0 to 100 where high score represent worst outcome. Least square mean and CI are from a repeated measures model on the response variable change from baseline in average symptom burden index score.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Intent-To-Treat Population includes all participants who are randomized into this study.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)","title":"Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score","type":"SECONDARY","unitOfMeasure":"Score on a sclae"}